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Mucoepidermoid  carcinoma  (MEC)  harbors  a  recurring  t(11;19) 
translocation  with  an  associated  novel fusion  oncogene-MECT1-MAML2.  The 
CRTC1-MAML2oncogene  disrupts  normal  cell-cycle  and  differentiation, 
contributing to tumor development. The objectives of this study were to establish 
the  incidence  of  CRTC1-MAML2  fusion  in  Serbian  patients  and  estimate  its 
relevance as a genetic marker of MEC behavior. In this retrospective study, 20 
cases of MEC of salivary glands were tested for the presence of CRTC1-MAML2 
fusion using reverse transcriptase-polymerase chain reaction. Clinicopathological 
parameters and survival data were examined in relation  to fusion status.  The 
CRTC1-MAML2  fusion  was  detected  in  40%  of  MECs  and  its  presence  was 
associated exclusively with low-intermediate grade tumor histology (P = 0.02) 
and favorable clinical outcome, with 100 % overall survival rate (P=0.046).  The 
study has shown that the presence of the CRTC1-MAML2 fusion can serve as an 
additional diagnostic and prognostic marker for mucoepidermoid carcinomas.  602                                                                                                             GENETIKA, Vol. 46, No.2,601-610, 2014 
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INTRODUCTION 
The World Health Organization recognized twenty-four types of benign and malignant 
salivary gland tumors (EVESON et al., 2005). Mucoepidermoid carcinoma (MEC) represents 5% 
of  all  salivary  gland  tumors  and  20%  of  salivary  gland  malignancies  (GOODE  et  al.,  2005).  
Clinical monitoring of this tumor and its outcome prediction are complicated due to biological 
diversity and clinical heterogeneity (BELL et al., 2005). Seventy years after the first identification 
of MEC, a unique, standardized grading system does not exist (LUNA, 2006). Hence, “failure to 
diagnose” or “erroneous diagnosis” are not uncommon, leading to delayed or missed therapy or 
treatment  and  wrong  prognosis.  In  other  words,  MEC  remains  a  considerable  challenge  for 
pathologists,  and  additional  molecular  markers  that  could  contribute  to  better  diagnosis  and 
predict the natural history of these tumors are needed.  
Genetic research of mucoepidermoid carcinomas was mainly focused on a non-random 
t (11;19) (q21;p13) reciprocal translocation  which appeared as a possible hallmark of  MEC. 
This translocation generates CRTC1-MAML2 fusion in which the CREB-binding domain of the 
CREB  coactivator  CRTC1  (also  known  as  MECT1,  TORC1  or  WAMTP1)  is  fused  to  the 
transactivation  domain  of  the  Notch  coactivator  MAML2  (MITELMAN,  2000).  It  seems  that 
MECT1–MAML2 fusion induced activation of CREB is critical for cell transformation (TONON 
et  al.,  2003;  WU  et  al.,  2005).  A  CRTC3-MAML2  fusion  gene  resulting  in  the  same  MEC 
phenotype as CRTC1-MAML2 has been described as well (FEHR et al., 2008). 
The incidence of CRTC1–MAML2 fusion in salivary gland MEC reported in different 
studies varied considerably (between 38%–and 81%) (OKABE et al., 2006; MIYABE et al., 2009, 
JEE et al., 2013) and it was assumed that the t (11; 19) gene fusion product was present only in 
low- and intermediate-grade MECs (OKABE et al., 2006;  SEETHALA et al. 2010). Conversely, 
other studies have shown that the fusion gene could be found in high grade (HG) MEC as well, 
which sparked a debate on its prevalence and relevance (TIRADO et al., 2007; CHENEVERT et al., 
2011, NAKANO et al., 2013). The aim of this research was to assess the relevance of CRTC1-
MAML2 fusion as a potential genetic marker of tumor behavior in MECs in Serbian population.  
 
MATERIALS AND METHODS 
Patients and specimens 
Formalin-fixed,  paraffin-embedded  specimens  of  52  mucoepidermoid  carcinomas  of 
salivary glands resected in the period 2001-2010 at the Clinic of Maxillofacial Surgery, School 
of Dental Medicine, University of Belgrade were available for the analysis.  Prior to molecular 
genetics analyses, the cases were once more carefully reviewed in 2012 by two independent 
pathologists (Z.T. and T.L.) according to the criteria of the WHO Classification for Pathology 
and  Genetics  of  Head  and  Neck  Tumors  (EVESON et al.,  2005).  Upon revision,  15 cases  of 
alleged  high  grade  (HG) MEC  were  excluded  from  further  analysis.   After RNA  extraction 
additional  17  cases  had  to  be  excluded  because  of  insufficient  RNA  quantity  or  quality. 
Evaluable PCR-results were obtained for 20 cases of MEC. The study was approved by the 
Ethical Committee of the School of Dental Medicine, University of Belgrade (IRB: 36/10) and 
written informed consent was obtained from each patient in accordance with the Declaration of 
Helsinki. I.ILIC.DIMITRIJEVIC et al:   T(11;19) TRANSLOCATION IN MUCOEPIDERMOID CARCINOMA                603 
 
Clinicopathological data   
The following parameters were recorded for every patient: age, sex, primary tumor site, 
tumor size, metastases to regional lymph nodes, clinical stage, histological grade, and follow-up 
and the tumor specimens were histologically classified according to a 3-grade system described 
by BRANDWEIN et al. (2001). The tumor grade was determined from the sum of the point values 
assigned  to  each  of  the  following  histologic  elements:  cystic  component,  neural  invasion, 
necrosis, mitosis, and anaplasia. 
 
CRTC1-MAML2 fusion detection   
The  CRTC1-MAML2  fusion  transcript  was  detected  using  one  step  reverse 
transcription-polymerase  chain  reaction  (RT-PCR).  To  this  end,  microtome  sections  were 
prepared  from  paraffin-embedded  tissue  blocks  and  one  of  the  sections  was  stained  with 
hematoxylin/eosin (HE) for microscopic inspection by a pathologist. Tumor containing tissue 
was then microdissected, deparaffinized and RNA was extracted, using the RNeasy FFPE Kit 
(Qiagen, Hilden, Germany). The CRTC1-MAML2 specific RT-PCR was performed, using the 
Qiagen  OneStep  RT-PCR  kit  according  to  the  manufacturer  instructions  (Qiagen,  Hilden 
Germany). Primers used for detecting the CRTC1-MAML2 fusion transcript were the following:  
 
MECT1 For 5’-GCCTTCGAGGAGGTCATGA-3’ 
MAML2 Rev 5’-CTTGCTGTTGGCAGGAGA-3’. 
As a positive control for each sample wild type MAML2 was also amplified using the primers:  
MAML2 For 5’-GTAGCAATAATGGTGGCAGT-3’ 
MAML2 Rev 5’-CTTGCTGTTGGCAGGAGA-3’. 
 
PCR reactions were performed in an ABI 2720 Thermal Cycler (Applied Biosystems, Foster 
City, USA) using the following amplification conditions: after an initial denaturation step at 
94°C for 3 min, 35 cycles of 94°C for 45 sec, 55 °C for 30 sec, and 72° C for 30 sec were run 
followed by a final extension step of 10 min at 72°C. PCR products were run and analyzed using 
the ABI 3130 Genetic Analyzer and the Gene Mapper v. 4.0 Software (Applied Biosystems, 
Foster City, USA).  
 
Statistical analysis  
For general information about the sample usual descriptive statistic tests were used. The 
survival rate was calculated with the Kaplan–Meier method. All analyses were performed with 
the statistical package SPSS, version 18 (IMB statistics software). 
 
RESULTS 
Clinicopathological  characteristics  of  MECs  and  association  with  CRTC1-MAML2 
fusion 
The study sample included 12 male and 8 female patients diagnosed with MEC, with 
the age ranging from 15 to 81 years (mean 55.5 years). Primary MEC localization were major 
salivary glands in all 20 cases (parotid gland, submandibular and sublingual). Out of the 20 
confirmed MECs 7 had more than 2 cm in diameter and they were classified as clinical stages III 
and IV. Only 3 showed metastases to the regional cervical lymph nodes. Histologically, 9 cases 604                                                                                                             GENETIKA, Vol. 46, No.2,601-610, 2014 
were classified as low grade, 5 as intermediate grade and 6 as high grade. The CRTC1-MAML2 
fusion transcript was detected in 8 (40%) of the 20 MEC cases. Correlation of CRTC1-MAML2 
fusion with clinicopathological features of MEC is given in Table 1. The fusion positive cases 
were  associated  with  low-intermediate  histological  grade  (P  =  0.02).    Of  the  five  factors 
constituting the histological grade, two correlated significantly with the presence of the fusion 
transcript- absence of necrosis (P= 0.024) and a lesser degree of anaplasia (P= 0.024).  
Table 1. Distribution of epidemiological, clinical and histological characteristics of 20 MEC patients in 
relation to the presence/abscence of CRTC1-MAML2fusion 
Abbreviations:  NS, not significant; HPF, high-powered field 
           Variable 
 
MECT1 – MAML2 
fusion 
P 
Positive 
(n=8) 
Negative 
(n=12) 
Age (years)  Mean  50,25  59  NS 
Sex 
Male  3  9 
NS 
Female  5  3 
Tumour site 
Major  8  12 
NS 
Minor  0  0 
Tumour size 
>20 mm  7  7 
NS 
<20 mm  1  5 
Nodal status 
Positive  0  3 
NS 
Negative  8  9 
Clinical stage 
I, II  7  8 
NS 
III, IV  1  4 
Histological findings 
Histological grade 
Low  7  2 
0.02  Intermediate  1  4 
High  0  6 
Cystic component 
>20%  4  6 
NS 
<20%  4  6 
Neural invasion 
Positive  0  2 
NS 
Negative  8  10 
Necrosis 
Positive  0  6 
0.024 
Negative  8  6 
Mitoses 
>4 ⁄ 10 HPF  2  7 
NS 
<3 ⁄ 10HPF  6  5 
Anaplasia 
Positive  0  6 
0.024 
Negative  8  6 I.ILIC.DIMITRIJEVIC et al:   T(11;19) TRANSLOCATION IN MUCOEPIDERMOID CARCINOMA                605 
Factors affecting disease-free and overall survival 
 
The follow-up was 138 months. At the last medical visit 10 patients were alive with no 
evidence of disease and 4 were alive with the disease. Among patients who died, 4 died from 
disease and 2 from other cause.  None of the patients with CRTC1-MAML2 fusion-positive MEC 
died of the tumor.   
Kaplan-Meier  analysis  for  disease-free  survival,  showed  that  MEC  patients  with 
positive CRTC1-MAML2 fusion transcript had 100 % survival rate (P= 0.002) (Table 2). Cases 
negative for the fusion had the following survival rates: 89% in histological grade I, 60% in 
grade II and 17% in grade III. As expected, patients with advanced tumor size (P=0,001) and 
clinical stage III/IV (P=0.003) showed low rate of disease-free survival. Low rate of disease-free 
survival was also observed in cases with tumor necrosis (P=0.001), neural invasion (P=0,006), 
anaplasia (P=0.003) and increased mitotic index (P=0,003). The Kaplan-Meier analysis showed 
a  statistically  significant  association  between  several  variables  and  survival  rates  (Table  2), 
including the fusion status (Fig. 1).  
 
 
 
 
Figure 1. Kaplan Meier representation of MEC patients overall survival in relation to the presence/absence 
of CRTC1-MAML2 fusion ranscript. 
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Table 2. Survival analysis in MEC patients in relation to clinical, histological and genetic data 
Abbreviations:  *NS, not significant; 
†HPF, high-powered field 
 
DISCUSSION 
Specific  chromosomal  translocations  are  commonly  observed  in  hematopoietic  and 
mesenchymal  stromal  tumors  and  define  distinct  clinicopathological  entities.  Interestingly, 
translocations  are  rather  an  exception  than  a  rule  in  epithelial  tumors,  and  mucoepidermoid 
carcinomas  fall  into  less  than  1%  of  all  epithelial  cancers  with  a  recurrent,  pathogenic 
chromosomal aberration (MITELMAN, 2000). According to STENMAN (2005), FEHR et al., (2009) 
and  BHAIJEE et  al (2011)  CRTC1-MAML2  fusion  might  define a  distinct  clinicopathological 
subset of mucoepidermoid carcinomas. This opinion is corroborated by the present study which 
showed that the CRTC1-MAML2 fusion is associated with low-intermediate grade histology and 
favorable clinical outcome. 
Variable 
Variable's 
value 
Disease free survival (P)  Overall survival (P) 
MEC 
(n=20) 
MEC 
(n=20) 
Tumor size 
>20 mm 
0.001  0.008 
<20 mm 
Nodal status 
Positive 
NS  NS 
Negative 
Clinical stage 
I, II 
 0.003  0.031 
III, IV 
Histological 
grade 
Low  
0.006  NS  Intermediate 
High 
Cystic component 
>20% 
NS  NS 
<20% 
Neural invasion 
Positive 
0.006  NS 
Negative 
Necrosis 
Positive 
0.001 
 
0.002 
  Negative 
Mitoses 
>4 ⁄ 10 HPF
† 
 
<3 ⁄ 10HPF 
0.003  0.004 
Anaplasia 
Positive 
0.003  NS 
Negative 
MECT1-MAML2  Positive  0.002  0.046 
Negative I.ILIC.DIMITRIJEVIC et al:   T(11;19) TRANSLOCATION IN MUCOEPIDERMOID CARCINOMA                607 
The CRTC1-MAML2 fusion transcript was detected in 40% of Serbian patients with 
MEC which is in agreement with the study of OKABE et al. (2006) who found 34% of fusion 
positive cases in their MEC sample, but it is a significantly lower percentage than reported by 
TIRADO et al. (2007), SCHWARZ et al. (2011), JEE et al. (2013). Our results demonstrated that the 
MECT1–MAML2 fusion was associated with low-intermediate grade tumor histology and a good 
prognosis which is also in agreement with other studies (OKABE et al., 2006;  MIYABE et al., 
2009). Similarly to our results, other groups have also shown that the fusion-positive cases had 
smaller tumor size, lower frequency of nodal metastasis and less advanced clinical stage (OKABE 
et al., 2006; OKUMARA et al., 2011). In addition, OKABE found that patients with fusion-positive 
tumors had significantly greater overall survival compared to fusion-negative patients. In this 
study patients with fusion-positive MECs also showed 100% overall survival. All high grade 
MECs were negative for the fusion transcript and all the patients with HG MEC died within the 
first five years after the diagnosis.  
Yet, some authors found a relatively high prevalence of fusion transcripts in high grade 
MECs  (TIRADO  et  al.,  2007;  MIYABE  et  al.,  2009).  One  of  the  possible  reasons  for  this 
discrepancy  is  the  absence  of  a  uniform  classification  system  and  frequent  misdiagnosis  of 
various  tumors  (such  as  squamous  cell  carcinoma  or  adenosquamous  carcinoma),  as  “high-
grade” MECs (BRANDWEIN et al., 2000; CHENEVERT et al., 2011).  Two-tiered and three-tiered 
systems of MEC grading are in use (BAI et al. 2013), which may lead to confusion. BEHBOUDI et 
al.  (2006)  and  OKUMURA  (2011)  among  others  suggested  the  introduction  of  molecular 
classification of MECs in which MECT1–MAML2 fusion status would serve as an additional 
diagnostic tool for distinguishing molecular subtypes of this tumor.  
The results of a recent study using high-resolution array-based comparative genomic 
hybridization revealed that low-grade MECs had significantly fewer copy number alterations 
compared to high grade MECs and regardless of their histological grade, fusion -positve MECs 
had a much more stable genome then fusion-negative MECs (JEE et al., 2013).  
The  great  majority  of  MECs  are  treated  by  surgical  resection  with  radiation  as  an 
adjunct  therapy  (SPIRO,  1998).  Determination  of  CRTC1-MAML2  fusion  could  have  clinical 
benefits. Preoperative RT-PCR analysis using tumor material obtained by fine-needle aspiration 
(JAYARAM et al., 1994) could be clinically useful and improve therapeutic strategies.  A new 
protocol  should  be  approved  indicating  that  radical  surgical  resection  with  a  postoperative 
radiotherapy is required for aggressive tumors such as fusion negative HG MECs. On the other 
hand, fusion positive MECs should undergo a less radical surgical resection with preservation of 
the facial nerve and without postoperative radiotherapy.  It has been shown that expression of 
CRTC1-MAML2 fusion is essential for tumor growth in fusion positive carcinomas (KOMIYA et 
al. 2006), making the fusion a potential therapeutic target. 
There is a limited number of publications on the CRTC1-MAML2 fusion and its possible 
role as a diagnostic and prognostic tool obtained on European populations. This is the first report 
on  the  prevalence  of  CRTC1-MAML2  fusion  in  Serbian  patients  with  mucoepidermoid 
carcinomas  and  it  represents  a  significant  contribution  to  the  extremely  scarce  genetics  of 
salivary gland tumors in Serbian population (MILAŠIN et al. 1993, NIKOLIĆ et al. 2013). 
In summary, the fusion may be considered as a molecular marker in this heterogeneous 
group of salivary gland tumors, i.e. fusion positive and fusion negative MECs should be viewed 
as distinct clinicopathological entities and treated with apposite therapies.  
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Izvod 
Kod  velikog  broja  mukoepidermoidnih  karcinoma  (MEK)  pljuvačnih  žlezda  detektovana  je 
t(11;19) hromozomska translokacija koja vodi nastanku CRTC1-MAML2 fuzionog produkta sa 
onkogenom aktivnošću koji remeti ćelijski ciklus i diferencijaciju dovodeći do razvoja tumora. 
Ciljevi ove studije bili su da se ispita učestalost CRTC1-MAML2 fuzije kod naših pacijenata 
obolelih od MEK-a i da se proceni značaj fuzije kao potencijalnog markera biološkog ponašanja 
ovih maligniteta. U ovoj retrospektivnoj studiji 20 slučajeva MEK-a bilo je testirano na prisustvo 
CRTC1-MAML2  fuzionog  transkripta  koristeći  reverznu  transkriptazu-  lančanu  reakciju 
polimeraze  (RT-PCR). Ispitivana  je  korelacija  CRTC1-MAML2  fuzionog  statusa  sa  kliničko-
patološkim karakteristikama tumora kao i vreme preživljavanja pacijenata sa MEK-om. CRTC1-
MAML2  fuzija  je  detektovana  u  40%  slučajeva  i  pokazana  je  njena  povezanost  sa  niskim 
odnosno srednjim histološkim  gradusom  karcinoma (P  = 0.02),  kao i  sa 100%-nom stopom 
preživljavanja  (P=0.046).  CRTC1-MAML2  fuzioni  status  u  mukoepidermoidnom  karcinomu 
pljuvačnih  žlezda  pokazao  se  kao  koristan  dopunski  parameter  za  pouzdaniju  dijagnozu  i 
prognozu.  
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